Navigation Links
PDL BioPharma Announces Fourth Quarter and Full Year 2009 Financial Results and Provides First Quarter 2010 Revenue Guidance
Date:3/2/2010

First Quarter 2010 Revenue Guidance

PDL will continue to provide revenue guidance on a quarterly basis at the beginning of the third month of each quarter for that quarter, as it did in 2009.  

Revenue guidance for the first quarter of 2010 is of $62 million as compared with actual results $62.6 million for the same period in 2009.  Included in first quarter results in 2009 was $17.1 million from MedImmune for sales of Synagis. The Company's first quarter 2010 guidance does not include royalties for Synagis due to ongoing legal disputes with MedImmune.  Excluding MedImmune, anticipated first quarter 2010 revenue grew by more than 35 percent over the first quarter of 2009.  The growth is primarily driven by increased fourth quarter 2009 sales of Avastin, Herceptin, Lucentis, Tysabri and Actemra for which PDL received royalties in the first quarter of 2010.  

Reported sales of Avastin and Herceptin increased 18 percent and 11 percent, respectively, when compared to the same period for the prior year. Also contributing to increased Avastin and Herceptin royalties are product sales that are ex-U.S. manufactured and sold and for which PDL re
'/>"/>

SOURCE PDL BioPharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. ClearTrial Launches New Service to Bring Speed and Accuracy in Clinical Trial Planning Within Reach of Smaller Biopharma Companies
2. Indiana Biopharmaceutical Service Providers Maintain Steady Growth Despite Industry Challenges
3. SynCo Bio Partners Signs New Manufacturing Agreements to Supply the US Market; Securing its Position as a Market Leader in Microbial Biopharmaceutical Contract Production
4. ClearTrial to Demonstrate Dramatic Gains in Clinical Outsourcing Efficiency Achieved by Biopharmaceutical Companies at European Outsourcing Event
5. Sinobiopharma Announces Second Quarter 2010 Financial Results
6. Microbix And Therapure Biopharma Form Partnership To Expand Water-Based Supplies To The Pharma Industry
7. YM BioSciences Inc. and Therapure Biopharma Inc. Announce Contract
8. Array BioPharma and Amgen Partner in Type 2 Diabetes
9. PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million
10. PDL BioPharma Announces Ex-Dividend Date of November 27 for Special Dividend
11. PDL BioPharma Announces Special Dividend Payment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... ATLANTA , Aug. 28, 2014   SunTrust ... of three industry veterans to its equity research ... "Our ongoing expansion in equity research demonstrates ... with unique insights to enhance their investment decision ... Equities at STRH.  "We continue to make significant ...
(Date:8/28/2014)... Aug. 28, 2014  Armetheon, Inc. ( www.armetheon.com ... mid- to late-stage cardiovascular drug candidates, today announced ... first round of financing. The Series A round ... Bioventures with participation from investors that included Atheneos ... Dr. Larry Hsu , the founder of ...
(Date:8/28/2014)... 27, 2014 Scientists, researchers, and technologists ... SPIE Laser Damage 2014 symposium. Marking its 46th ... lasers will run 14-17 September. The event is sponsored ... photonics . , The premier conference for basic and ... to optical materials will engage researchers and engineers from ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 Earlier this ... University in partnership with the U.S. Air Force ... biofuel. The results indicated that this type of fuel ... feedstock and will be important to America’s Eco friendly ... now has a mandate to become independent of foreign ...
Breaking Biology Technology:SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 2SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 3Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 3Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 2Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 2Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 4Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 5
... - Non-responder and Null Responder HCV patients -- ... -BRISBANE, Calif., April 21 InterMune, Inc. (Nasdaq: ... innovative clinical study of protease inhibitor ITMN-191 (R7227) ... referred to as the INFORM-1 study, has been ...
... Response Data from Dose-Escalation Study Presented at , ... 2009 -SOUTH SAN FRANCISCO, Calif. and DENVER, April ... PARD ), a biopharmaceutical company focused on oncology, ... a Phase 1 dose-escalation study of picoplatin in ...
... Data on novel pro-apoptotic agent presented at the ... Cancer Research -- University of Pennsylvania ... lines, highlighting AT-101,s inhibition of Mcl-1, also presented ... announced today that the results of preclinical studies ...
Cached Biology Technology:INFORM-1 Clinical Trial Amended to Further Explore Promising Direct Antiviral Regimen in HCV Patients 2INFORM-1 Clinical Trial Amended to Further Explore Promising Direct Antiviral Regimen in HCV Patients 3INFORM-1 Clinical Trial Amended to Further Explore Promising Direct Antiviral Regimen in HCV Patients 4INFORM-1 Clinical Trial Amended to Further Explore Promising Direct Antiviral Regimen in HCV Patients 5Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Picoplatin in Patients with Metastatic Colorectal Cancer 2Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Picoplatin in Patients with Metastatic Colorectal Cancer 3Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Picoplatin in Patients with Metastatic Colorectal Cancer 4Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Picoplatin in Patients with Metastatic Colorectal Cancer 5Ascenta Therapeutics Announces Results of Preclinical Evaluation of AT-406 in Multiple Cancer Models 2Ascenta Therapeutics Announces Results of Preclinical Evaluation of AT-406 in Multiple Cancer Models 3
(Date:8/28/2014)... Mayo Clinic researcher and his collaborators have developed an ... the process of re-engineering cells for biomedical investigation. CellNet ... methods to aid stem cell engineering. Details of CellNet ... in two back-to-back papers in the journal Cell ... of uses for all types of cell-based investigations and ...
(Date:8/28/2014)... (Maximizing Access to Research Careers) Program has announced ... of America,s 27th Annual Mouse Molecular Genetics Conference ... Pacific Grove, California. These awards are meant ... and scientists from underrepresented groups into the mainstream ... the participation of young scientists at the Genetics ...
(Date:8/28/2014)... N.C. -- Scientists have identified the developmental on-off switch ... that produce more than two-thirds of the world,s naturally ... be to see whether it is possible to manipulate ... , The study, appearing August 28 in ... small molecule called cyclic-di-GMP and a larger protein called ...
Breaking Biology News(10 mins):New tool aids stem cell engineering for medical research 2Small molecule acts as on-off switch for nature's antibiotic factory 2Small molecule acts as on-off switch for nature's antibiotic factory 3
... State University researchers have uncovered a pattern of distrust ... hospitals and midwives who are transporting their home-birth clients ... State University assistant professor Melissa Cheyney and doctoral student ... between physicians and midwives that is reflective of discord ...
... Phase I SBIR grant of $1,296,403 from the ... "Differential Phase Contrast Imaging" using the unique x-ray ... The grant will allow Lyncean to continue ... and its applications to new methods of imaging ...
... built a new tissue scaffold that can stimulate bone ... other joints. The scaffold could offer a potential ... such as arthritis, says Lorna Gibson, the Matoula S. ... of the research team with Professor William Bonfield of ...
Cached Biology News:Study reveals conflict between doctors, midwives over homebirth 2Study reveals conflict between doctors, midwives over homebirth 3Lyncean Technologies Inc. receives $1.2 M from NCRR to develop new imaging technique 2MIT: New tissue scaffold regrows cartilage and bone 2
CHIMAERIC HUMAN IgA2 ANTI NP...
... The Zero Background/Kan Cloning ... with kanamycin resistance for selection ... vector utilizes positive selection to ... contains all of the reagents ...
RABBIT ANTI RAT AQUAPORIN 5...
The Light Diagnostics Calicivirus Genotype 1&2 Typing OligoDetect assay is applicable for the qualitative detection of calicivirus RNA generated by an in-house validated in vitro nucleic acid amplifi...
Biology Products: